ClinicalTrials.gg
Not yet recruitingNCT07539987Updated Nov 19, 2026

Evaluation of a Novel Indoor Air Pollution Intervention Among Older Adults

An interventional study of Air Improvement and Real-time Monitoring for Wellness through Interactive Strategies and Education (AIRWISE) and Portable Air Cleaner (PAC) Control in Cardiovascular Diseases, Blood Pressure and Glycated Hemoglobin (HbA1c), sponsored by University of Montana. Not yet recruiting at 1 site in United States. Open to participants aged 55 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Montana · Not applicable, Interventional, and Prevention

How we know

Updated Nov 19, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
55 Years to 79 Years
Sex
All
01

Study summary

Particulate matter air pollution is the leading environmental risk factor of cardiovascular disease and is increasing in the Western United States due to more frequent and severe wildfires. Older adults are particularly susceptible to both air pollution exposures and the development of cardiovascular disease, and the older adult population in the United States is rapidly growing. Given the converging threats of worsening air quality and an aging population, this clinical trial will evaluate a novel, multifaceted indoor air quality intervention to improve cardiovascular health outcomes among older adults in the wildfire-impacted state of Montana.

Read the detailed description

Particulate matter (PM) air pollution is the leading risk factor of global disease burden and the largest environmental risk factor for premature death and cardiovascular disease (CVD). Older adults are particularly susceptible to air pollution exposures and the development of CVD as they often have underlying health conditions. PM levels are rising in the Western United States (US) as wildfires have increased, with up to 50% of fine PM (PM2.5; particles \<2.5 µm in diameter) in some Western regions now attributed to wildfires. Recent research indicates there is often a substantial increase in indoor PM2.5 when outdoor PM2.5 increases, including during wildfire events. Improving indoor air quality is critically important as US adults spend 90% of their time indoors where air quality is impacted by numerous indoor and outdoor air pollution sources. New strategies are needed to improve indoor air quality and CVD health outcomes, particularly as the US population rapidly ages and the number of susceptible older adults grows. There is evidence that filtering indoor air with portable air cleaners (PACs) can result in short-term PM2.5 improvements. However, evidence is limited that PAC use meaningfully improves health, particularly in studies of longer duration. In response to this need, the investigators have developed a household indoor air quality intervention called AIRWISE (Air Improvement and Real-time Monitoring for Wellness through Interactive Strategies and Education). AIRWISE promotes sustained improvements in indoor air quality through education, behavioral cues, and equipment including PACs and PM2.5 sensors that display real-time data. In this project, the investigators will evaluate the AIRWISE intervention among older adults in the wildfire-impacted US state of Montana. In Aim 1, the investigators will conduct a randomized trial to test the efficacy of the AIRWISE intervention on PREVENT (Predicting Risk of CVD EVENTs), a validated CVD risk score. The central hypothesis is that PREVENT will be improved among older adults who use AIRWISE compared to controls who use only PACs. The rationale is that the AIRWISE intervention will promote sustained improvements in indoor air quality and CVD risk, a significant advance beyond PACs alone that are widely recommended yet have inconsistent benefits on long-term health. In Aim 2, the investigators will use Aim 1 data to determine associations between indoor PM2.5 concentrations and PREVENT. The investigators will use additional models between PM2.5 and the individual components of PREVENT as outcomes in order to determine which risk factors are most impacted by PM2.5 and inform underlying subclinical mechanisms. In Aim 3, the investigators will model the economic costs and benefits of indoor PM2.5 improvements and the AIRWISE intervention to inform policy-level action. With the converging threats of increasing air pollution due to wildfires and an aging US population, this project will contribute to identifying actionable strategies to improve indoor air quality and decrease CVD risk among older adults.

02

Conditions studied

  • Cardiovascular Diseases
  • Blood Pressure
  • Glycated Hemoglobin (HbA1c)
  • Cholesterol
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Indoor Air Quality
  • Particulate Matter
  • Health Behavior
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 154 is above the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

University of Montana is the lead sponsor of 28 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 55-79 years of age one primary residence (5+ days per week)
  • have an electronic device, email address, and reliable internet at home for survey submission

Exclusion criteria

Exclusion Criteria:

  • current smoking of any kind or living in a household with someone who currently smokes
  • current use of a portable air cleaner unit at home
  • plans to move in the next year
  • previous physician-diagnosed cardiovascular disease (coronary heart disease [myocardial infarction], stroke, or heart failure)
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
154 participants (estimated)

Study arms

  • Experimental
    AIRWISE Intervention

    Participants randomized to the AIRWISE Intervention group will use AIRWISE in their homes for 12 months. The AIRWISE group will use two PACs to filter indoor air and two optical PM2.5 sensors with lights that change color in real time according to AQI. In addition, automated outdoor air quality alerts are sent via text and email when outdoor AQI goes above 75 (mid-point of the Moderate AQI category). Outdoor air quality will be referenced from the Environmental Protection Agency or PurpleAir monitor nearest to the participant's home. Based on the indoor and outdoor AQI levels, participants will reference a decision matrix and educational materials to make informed decisions on improving indoor air quality. Education and behavioral strategies are delivered through multiple approaches, including visual aids, handouts, videos, and a magnet with the decision matrix that can be placed in an accessible location in the home.

    Behavioral: Air Improvement and Real-time Monitoring for Wellness through Interactive Strategies and Education (AIRWISE)

  • Active comparator
    PAC Control

    Participants randomized to the PAC Control group will use two PACs in their home without additional AIRWISE equipment/education. After randomization, they will be given instructions on study procedures and using the PAC units according to manufacturer recommendations. PAC Control group participants will not receive further education on air quality or recommendations on PAC use, nor will they receive additional equipment or outdoor AQI alerts. They will receive PurpleAir sensors without an AQI light that are for data collection purposes only, and they will not have access to the data throughout the study. Control participants will use and maintain the PACs at their own discretion. At the end of their participation, they will have the option of receiving the additional AIRWISE components.

    Other: Portable Air Cleaner (PAC) Control

Interventions

  • BehavioralAir Improvement and Real-time Monitoring for Wellness through Interactive Strategies and Education (AIRWISE)

    The AIRWISE intervention consists of a 3-pronged approach grounded in the Health Belief Model (HBM) to improve residential indoor air quality through education, equipment, and behavioral cues. To reinforce cues to action, AIRWISE uses alerts from air quality sensors, prompting timely behavioral responses. Specifically, indoor and outdoor air quality alerts act as behavioral cues to promote active engagement and reference a decision matrix with specific recommendations based indoor and outdoor air quality. Recommendations on the decision matrix include simple strategies to reduce air pollution exposures, including increasing use and fan speed of portable air cleaners, opening or closing windows to change ventilation, and changing activities such as physical activity, cooking, and cleaning. This integrated approach promotes sustained behavior change by aligning with all key HBM constructs.

  • OtherPortable Air Cleaner (PAC) Control

    Participants will use two PACs in their home according to manufacturer recommendations. PAC Control group participants will not receive further education on air quality or recommendations on PAC use, nor will they receive additional equipment or outdoor AQI alerts. Control participants will use and maintain the PACs at their own discretion.

06

What researchers measure

Primary outcomes

  1. Predicting Risk of CVD EVENTs (PREVENT) Score

    Validated cardiovascular disease (CVD) risk score called Predicting Risk of CVD EVENTs (PREVENT). The score is a percentage ranging from 0 to 100 that indicates percentage risk of developing CVD, with higher scores indicating higher risk of developing CVD.

    Time frame: 0, 6, 12 months

Secondary outcomes

  1. Life's Essential 8 (LE8) Score

    Validated metric of cardiovascular health called Life's Essential 8 (LE8). The score ranges from 0 to 100, with higher scores indicating better cardiovascular health and lower risk of adverse cardiovascular outcomes.

    Time frame: 0, 6, 12 months

  2. Indoor PM2.5

    Fine particulate matter (PM2.5), or particles that are less than 2.5 micrometers in aerodynamic diameter and a primary component of air pollution

    Time frame: Continuous at 2-minute intervals

  3. Indoor VOCs

    Volatile Organic Compounds (VOCs), a component of air pollution

    Time frame: Continuous at 2-minute intervals

  4. Glycated hemoglobin

    A measure of blood sugar levels measured through venous blood draw and used to calculate the primary PREVENT outcome

    Time frame: 0, 6, 12 months

  5. Estimated Glomerular Filtration Rate

    A measure of kidney function measured through venous blood draw and used to calculate the primary PREVENT outcome

    Time frame: 0, 6, 12 months

  6. Total cholesterol

    Measured through venous blood draw and used to calculate the primary PREVENT outcome

    Time frame: 0, 6, 12 months

  7. HDL cholesterol

    High-density lipoprotein cholesterol measured through venous blood draw and used to calculate the primary PREVENT outcome

    Time frame: 0, 6, 12 months

  8. LDL cholesterol

    Low-density lipoprotein cholesterol measured through venous blood draw and used to calculate the primary PREVENT outcome

    Time frame: 0, 6, 12 months

  9. CRP

    C-reactive protein, a measure of inflammation measured through venous blood draw

    Time frame: 0, 6, 12 months

  10. ESR

    Erythrocyte sedimentation rate, used as a measure of inflammation measured through venous blood draw

    Time frame: 0, 6, 12 months

  11. Uric acid

    Used as a measure of inflammation measured through venous blood draw

    Time frame: 0, 6, 12 months

  12. CBC

    Used as a measure of inflammation measured through venous blood draw

    Time frame: 0, 6, 12 months

  13. Systolic and diastolic blood pressure

    A risk factor for CVD and used to calculate the primary PREVENT outcome

    Time frame: Measured at baseline, followed by once per month through study completion, for a total of 13 measurements.

  14. Health symptoms

    Health symptoms will be reported in a questionnaire and used as a measure of quality of life. The questionnaire includes 6 questions and asks about recent illness and frequency of symptoms including eye irritation, blurred vision, wheezing, cough, throat irritation, difficulty breathing, excessive mucus, nose irritation, and headache.

    Time frame: Measured at baseline, followed by once per month through study completion, for a total of 13 measurements.

  15. Physical activity

    A risk factor for cardiovascular health and used to calculate the secondary LE8 outcome. Physical activity will be reported in a questionnaire. The questionnaire includes 12 questions and asks about type, duration, and location of recent physical activities.

    Time frame: Measured at baseline, followed by once per month through study completion, for a total of 13 measurements.

  16. Sleep quality

    A risk factor for cardiovascular health and used to calculate the secondary LE8 outcome. Sleep quality will be reported in a questionnaire. The questionnaire includes 9 questions and asks about duration, quality, barriers, and facilitators of sleep over the previous month.

    Time frame: Measured at baseline, followed by once per month through study completion, for a total of 13 measurements.

  17. Diet

    A risk factor for cardiovascular health and used to calculate the secondary LE8 outcome. Diet will be reported in a questionnaire. The questionnaire includes 16 questions and asks about the recent frequency and amount of consuming 16 different types of foods.

    Time frame: Measured at baseline, followed by once per month through study completion, for a total of 13 measurements.

  18. BMI

    A risk factor for cardiovascular health and used to calculate the secondary LE8 outcome

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2027; primary completion for Jul 2030, 39 months later.

Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 39 months is above that.

Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Apr 2027, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2026
First posted
Apr 20, 2026
StartEst.
Apr 2027was Aug 2026
Primary completionEst.
Jul 2030
CompletionEst.
Jul 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Apr 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Aug 2026→Apr 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07539987
Lead sponsor
University of Montana
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Apr 2027 (estimated)
Primary completion
Jul 2030 (estimated)
Completion
Jul 2030 (estimated)
Last update
Nov 19, 2026

Study contacts

Ethan S Walker, PhD
Contact
ethan.walker@umontana.edu
406-243-2063

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion